Unveiling anaphylatoxins: Pioneering cancer therapies through complement system insights
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025-10 · 1880 (5) · 189436
DOI: 10.1016/j.bbcan.2025.189436 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025-10. Verfasst von Jiamu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, PR China. Hauptthemen laut MEDLINE: Neoplasms, Anaphylatoxins, Complement System Proteins, Complement C5a. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 206 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The complement system, a cornerstone of innate immunity, plays pivotal roles in both defense and pathology, particularly through its anaphylatoxins, C3a and C5a. These small peptides, generated during complement activation, not only mediate pro-inflammatory responses but also contribute to the progression of various cancers by modulating the tumor microenvironment (TME). Anaphylatoxins influence tumor cell proliferation, epithelial-mesenchymal transition, angiogenesis, immune suppression, and therapy resistance via key signaling pathways such as PI3K/AKT, MEK/ERK, and p38 MAPK. This review summarizes recent findings on the roles of C3a and C5a in different tumor types, including glioma, lung cancer, melanoma, breast cancer, and hematological malignancies, highlighting their potential as biomarkers and therapeutic targets. Additionally, we discuss the development of anaphylatoxin inhibitors, their clinical applications, and the synergistic effects of combining these inhibitors with immune checkpoint blockade therapies. A deeper understanding of anaphylatoxin-mediated mechanisms may provide novel strategies for cancer diagnosis, prognosis, and treatment, paving the way for targeted and combination therapies to overcome tumor progression and immune evasion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, PR China.
- Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, PR China; Department of Neurosurgery, Liaoning Cancer Hospital and Institute, Cancer Hosp…
- Department of Neurosurgery, The First Hospital of China Medical University, Nanjing Street 155, Heping District, Shenyang 110001, PR China. Electronic address: ztjing@cmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, J., Li, X., Hu, J., You, Z., & Jing, Z. (2025). Unveiling anaphylatoxins: Pioneering cancer therapies through complement system insights. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1880(5), 189436. https://doi.org/10.1016/j.bbcan.2025.189436
Vancouver
Li J, Li X, Hu J, You Z, Jing Z. Unveiling anaphylatoxins: Pioneering cancer therapies through complement system insights. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025;1880(5):189436. doi:10.1016/j.bbcan.2025.189436
BibTeX
@article{Li2025,
author = {Li, Jiamu and Li, Xinqiao and Hu, Jinpeng and You, Zinan and Jing, Zhitao},
title = {Unveiling anaphylatoxins: Pioneering cancer therapies through complement system insights},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
volume = {1880},
number = {5},
pages = {189436},
doi = {10.1016/j.bbcan.2025.189436}
}
EUVIMED